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This trial was conducted to assess the activity and tolerability of the gemcitabine, epirubicin, taxol triplet combination in patients with
operable breast cancer. After core biopsy, 43 women with stage II–IIIA breast cancer were treated with gemcitabine 1000mgm
 2
over 30min on days 1 and 4, epirubicin 90mgm
 2 as an intravenous bolus on day 1, and taxol 175mgm
 2 as a 3-h infusion on day 1,
every 21 days for four cycles. The primary end point was the percentage of pathological complete responses (pCR) in the breast;
secondary end points were tolerability, clinical response rates, overall and progression-free survival, tumour biomarkers before and
after primary chemotherapy (PCT). All patients were included in safety and survival analyses; 41 eligible patients were evaluated for
response. The overall clinical response rate was 87.8% (95% CI 77.8–97.8), with 26.8% complete responses (95% CI 13.3–40.3). A
pCR in the breast was observed in six patients (14.6%; 95% CI 3.8–25.4); 15 patients (36.6%; 95% CI 21.9–51.3) had negative axillary
lymph nodes. Grade 4 neutropenia was observed in 67.4% of the patients; febrile neutropenia occurred in 1.9% of cycles (granulocyte
colony-stimulating factor was used in 3.2% of the cycles to shorten the duration of neutropenia). A statistically significant difference
between Mib-1 at baseline (X20% in 71.4% of the patients) and at definitive surgery (28.6%, Po0.05) was observed. The
gemcitabine, epirubicin, taxol regimen is active and well tolerated as PCT for operable breast cancer. This combination allows the
administration of full doses of active agents with a low incidence of febrile neutropenia.
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Primary chemotherapy (PCT) was initially employed to treat
locally advanced and/or inflammatory breast carcinomas. An
objective response was observed in more than 50% of the patients,
radical surgery was feasible in most of the cases, and prolonged
disease-free and overall survival were reported (Hortobagyi and
Buzdar, 1997; Ueno et al, 1997; Baldini et al, 2003). More recently,
PCT has been used in patients with large primary tumours to avoid
radical mastectomy. Again, a significant proportion of patients
experienced an objective response and could be treated with
conservative surgery (Bonadonna et al, 1990, 1998; Smith et al,
1995; Mauriac et al, 1999). Interestingly, in about 10% of cases,
tumour shrinkage was so massive that no viable tumour cells were
found at definitive pathology; the achievement of a pathological
complete response (pCR) was associated with a prolonged disease-
free and overall survival (Fisher et al, 1998; Kuerer et al, 1999;
Pierga et al, 2000). So far, randomised clinical trials have failed to
show a survival advantage for PCT vs postoperative treatment;
however, other advantages such as the increased rate of breast
conservative surgery and the prognostic value of pCRs have been
confirmed (Scholl et al, 1994; Fisher et al, 1997; Kuerer et al, 1999;
Pierga et al, 2000; van der Hage et al, 2001; Mauri et al, 2005).
Primary chemotherapy is now considered the standard treat-
ment for locally advanced and inflammatory breast carcinoma, a
reasonable approach for operable breast cancer with unfavourable
breast/tumour ratio and an acceptable alternative for all early breast
cancer patients who are candidates for adjuvant chemotherapy.
Apart from these established roles in routine practice, PCT
represents an interesting research tool which allows investigators
to: (1) test new regimens with a validated short-term end point
(pCR); (2) design tailored treatments based on the observed
response; (3) identify tumour biomarkers with prognostic and/or
predictive value.
We have recently shown that the combination of gemcitabine
plus epirubicin and taxol (GET) is feasible and extremely active in
metastatic breast cancer (Conte et al, 2001; Cappuzzo et al, 2004).
Based on the high overall and complete response rates obtained
with this regimen, we have designed a phase II trial to evaluate the
activity of GET as PCT in operable breast cancer. An ancillary
study was the evaluation of the tumour biological profile before
and after chemotherapy. In particular, markers of proliferation
have already been validated as valuable predictors of response to
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sboth PCT and endocrine therapy, and were therefore included in
our study (Esteva and Hortobagyi, 2004; Burcombe et al, 2005;
Dowsett et al, 2005).
Preliminary results from this trial have been previously reported
(Conte et al, 2003).
PATIENTS AND METHODS
Patients with histologic diagnosis of breast cancer who met the
following criteria were eligible: stage II–IIIa (tumour size X2cm)
determined by physical examination and mammography; adequate
bone marrow reserve (white blood cell count X4.0 10
9l
 1,
platelets X100 10
9l
 1, haemoglobin X100gl
 1); adequate renal
and hepatic function (creatinine o1.5mgdl
 1, alanine trans-
aminase or aspartate transaminase o1.5 upper limit of normal
(ULN)); normal cardiac function determined by electrocardiogram
and left ventricular ejection fraction (L-VEF); World Health
Organization (WHO) performance status p2; aged 18–70 years;
compliance and geographic proximity; childbearing potential
terminated or attenuated by use of an approved contraceptive
method; written informed consent. The noneligibility criteria were:
locally advanced disease (stage IIIB) or inflammatory breast
carcinoma; multifocal breast carcinoma; active infection; calcium
above the ULN; presence of distant metastases; other serious
medical illness (including history of congestive heart failure,
myocardial infarction, symptomatic cardiac arrhythmias). Pre-
study staging included physical examination, mammography
and/or ultrasonography of the breast, chest radiography, bone
scan, liver ultrasonography, echocardiography and haematological
blood tests.
Treatment plan
After core biopsy, patients were treated according to the following
schedule: gemcitabine 1000mgm
 2 over 30min on days 1 and 4,
epirubicin 90mgm
 2 as an intravenous (i.v.) bolus on day 1 and
taxol 175mgm
 2 as a 3-h infusion on day 1, every 21 days for four
cycles. In order to prevent severe hypersensitivity reactions,
patients received a premedication with dexamethasone 20mg i.m.,
orphenadrine 50mg i.m. and cimetidine 300mg i.v.
Complete blood count was determined on day one of each
cycle and then twice a week. Treatment was permitted if white
blood cell count was X3.0 10
9l
 1, absolute neutrophil count
was X1.5 10
9l
 1 and platelet count was X100 10
9l
 1; if these
values were not reached, treatment was delayed until recovery. All
drugs were reduced by 25% in case of febrile neutropenia requiring
hospitalisation and/or i.v. antibiotics, grade 4 thrombocytopenia
lasting more than 3 days and/or associated with bleeding, or
grade 4 neutropenia lasting more than 7 days. In case of grade 3
nonhaematological toxicities (except nausea/vomiting and alopecia),
all drugs were reduced by 25%; all drugs were reduced by 50% for
grade 4 toxicity. In the case of grade 1 neurotoxicity, taxol was
reduced to 135mgm
 2, and in the case of grade 2 neurotoxicity,
taxol was discontinued. The protocol permitted use of granulocyte
colony-stimulating factor (G-CSF) as prophylaxis after episodes
of febrile neutropenia. Patients with hypersensitivity reactions
received supportive measures and were treated again with taxol at
a slower rate of infusion.
Patients who developed progressive disease were taken off the
study.
Surgery
After four cycles of chemotherapy, breast surgery was performed
according to local procedures. Patients received either modified
radical mastectomy or lumpectomy with axillary dissection of level
I–II axillary lymph nodes.
Adjuvant therapy
Adjuvant postoperative chemotherapy was left to the discretion
of the treating physician; however, two additional courses of
chemotherapy were recommended in cases of positive lymph
nodes. Premenopausal receptor-positive patients received tamoxi-
fen 20mg daily for 5 years plus luteinising hormone-releasing
hormone inhibitors for 2 years. Postmenopausal receptor-positive
patients received tamoxifen 20mg daily for 5 years.
In cases of breast conservative surgery, postoperative irradiation
with a 4–6MeV linear accelerator or modern cobalt-60 unit was
administered. Radiotherapy was started after completing chemo-
therapy.
Study analysis
Assessment of response Clinical assessment of tumour and nodal
size was performed by physical examination, mammography and/
or ultrasonography before starting chemotherapy, and again
before surgery.
Clinical response was defined as follows: complete response is
the disappearance of all clinically detectable disease; partial
response is a X50% decrease in the products of the two largest
tumour diameters; stable disease reflects changes in tumour
burden that do not indicate a progressive disease or clinical
complete or partial response. Progressive disease was defined as at
least a 25% increase in the sum of the products of bidimensionally
measurable disease or the appearance of new lesions.
Pathological complete response was defined as no histologic
evidence of invasive or noninvasive tumour cells in the breast.
Toxicity was evaluated according to the common toxicity criteria
of the National Cancer Institute. Progression-free and overall
survivals were calculated according to Kaplan–Meier curves from
day 1 of the first cycle. All registered patients were included in the
analysis of toxicities and survival. Eligible patients only were
included in the primary efficacy analysis.
Biological study The following biological markers were assayed at
baseline and on the surgical specimens: hormone receptor, Mib-1,
Scarff–Bloom–Richardson grade and Her-2-neu expression. All
the biological markers were measured in a centralised laboratory.
End points The primary end point was the pCR rate. Secondary
end points were: toxicities, overall response rate, survival and
progression-free survival, and tumour biological profile before and
after PCT.
Statistical methods Simon’s optimal two-stage design for phase II
clinical trial was used to calculate the sample size, with the
principal study end point being the pCR rate. The sample size
was calculated on the following assumptions: a error¼0.05,
b error¼0.10; P0 (clinically uninteresting true response rate)
and P1 (sufficiently promising true response rate) were set at 5 and
20%, respectively. In all, 21 patients had to be enrolled in the first
stage: if p1 pCR were observed, the accrual was stopped. In case of
X2 pCR, 20 more patients were entered at the second stage. The
regimen was considered sufficiently active to deserve further
studies if X5 pCRs were seen.
RESULTS
Patient characteristics
A total of 44 women with stage II–IIIA disease from five Italian
institutions were enrolled into the study; one patient was not
included in the full analysis set for refusal. In all, 41 patients were
eligible, two patients were not included in the primary efficacy
analysis due to the existence of bilateral breast carcinoma. The
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scharacteristics of the patients are shown in Table 1. The median
age was 48 years (range 26–66 years); the majority of patients had
stage II disease (67.4%) and positive hormone receptors (79.1%).
Baseline hormonal status was not available in one patient who
achieved a pCR. Median tumour size at the baseline was 4cm
(range 2–7cm). Mib-1 was X20% in 23 (53.5%), o20% in 13
(30.2%) and not known in seven patients. Her-2 status was positive
in five (11.6%), negative in 25 (58.1%) and unknown in 13 patients.
Response to chemotherapy
All eligible patients were evaluable for response. The overall
clinical response rate was 87.8% (95% CI 77.8–97.8), with 61% of
the patients experiencing a partial response and 26.8% (95% CI
13.3–40.3) a complete response; stable disease was observed in five
patients (12.2%).
A pCR was observed in six patients (14.6%) (95% CI 3.8–25.4);
15 patients (36.6%) (95% CI 21.9–51.3) had negative axillary
lymph nodes.
The pCR rate was analysed as a function of pretreatment clinical
stage and biological characteristics. Two pCRs were observed
among five patients with tumours less than 3cm (40%), three
among 25 women with tumour size between 3 and 5cm (12%), and
one in 11 patients with tumours larger than 5cm (9.1%). The pCR
rate was 9.7% (three out of 32) in oestrogen receptor-positive and
25% (two out of eight) in oestrogen receptor-negative tumours,
17.4% (four out of 23) in Mib-1 X20 and 7.7% (one out of 13) in
Mib-1 o20% tumours, 20% (one out of five) and 4% (one out of
25) in Her-2-positive and -negative tumours, respectively; none of
these differences reached statistical significance.
At a median followup of 29 months (range 12.2–51), nine
patients had developed progressive disease and three patients had
died (Figure 1).
Toxicity
In all, 43 patients were evaluable for toxicity. During the study, 172
cycles of chemotherapy were administered and were evaluable for
toxicity.
The main haematological toxicity was neutropenia, with grade 4
episodes observed in 67.4% of the patients. Febrile neutropenia
occurred in 1.9% of cycles, while G-CSF was administered in 3.2%
of the cycles to shorten the duration of neutropenia. Only one
episode of grade 3 anaemia was observed, while thrombocytopenia
was mild, with 9.3% of patients experiencing a grade 3 toxicity
(Table 2). One red blood cell transfusion was performed, but no
platelet transfusion was required. Delays and dose reductions
were performed in 10.3 and 9.7% of the cycles, respectively. The
administered dose intensity of each individual drug was 95, 98 and
97% for gemcitabine, epirubicin and taxol, respectively.
No episode of grade 4 nonhaematological toxicity occurred.
Nausea/vomiting and mucositis grade 3 were observed in 9.3 and
7% of the patients, respectively. Grade 1–2 neuropathy was
observed in 18.6% of the patients. Cutaneous toxicity was mild,
Table 1 Patient characteristics
Number of patients enrolled 44
Patients eligible 41
Median age (range) 48 (26–66)
Median tumour size, cm (range) 4 (2–7)
Hormonal receptor status, n (%)
Positive 34 (79.1)
Negative 8 (18.6)
Unknown 1 (2.3)
Mib-1 status, n (%)
Positive (X20%) 23 (53.5)
Negative (o20%) 13 (30.2)
Unknown 7 (16.3)
Her 2 status, n (%)
Positive 5 (11.6)
Negative 25 (58.1)
Unknown 13 (30.2)
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Figure 1 Progression-free survival and overall survival.
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swith 41.9% of the patients experiencing grade 1–2 toxicity
(Table 3).
No clinical cardiac toxicity or significant decrease of L-VEF was
observed.
Surgery
All the patients underwent surgery for breast cancer. In all, 19
patients (44%) were treated with lumpectomy and axillary node
dissection, and 24 patients (56%) received modified radical
mastectomy.
Biological study
The expression of hormonal receptor status and nuclear grading
were not modified by chemotherapy. A statistically significant
difference between Mib-1 at baseline and at definitive surgery was
observed: Mib-1 X20% in 71.4% of the patients at baseline and
in 28.6% at surgery (Po0.05). Her-2-neu expression was also
modified by chemotherapy even if the difference was not
significant: it was positive in 21% of the patients at baseline and
in 10.5% at surgery. Biological data are summarised in Table 4.
DISCUSSION
International recommendations have been developed to support
the use of PCT in routine practice (Kaufmann et al, 2003);
however, this approach still represents an interesting research tool
that allows a reliable intermediate end point such as pCR to be
measured, treatments to be designed and tailored on response, and
tumour biomarkers with potential prognostic or predictive value
to be investigated. Our study was designed to assess the efficacy
and tolerability of the GET regimen as PCT in operable breast
carcinoma. This combination was initially tested in metastatic
breast cancer patients, showing an interesting activity with
response rates ranging from 62 to 92%, with 10–31% CR (Conte
et al, 2001; Zielinski et al, 2003; Cappuzzo et al, 2004). This
regimen was found to be well tolerated. The majority of the
patients experienced a grade 4 neutropenia; however, the incidence
of febrile neutropenia was very low (5–12%) and growth factors
were rarely used.
This trial confirms that the GET regimen can be safely
administered at full doses with a few patients requiring dose
adjustments. The incidence of grade 4 neutropenia was high
(67.4% of the patients); however, it was short lasting, rarely
requiring G-CSF administration (3.2% of cycles), and resulted in
very few episodes of febrile neutropenia (1.9% of cycles),
significantly lower than that observed in an adjuvant trial with a
three-drug regimen including docetaxel, doxorubicin and cyclo-
phosphamide (Martin et al, 2003). The reduced myelotoxicity of
paclitaxel vs docetaxel, epirubicin vs doxorubicin, gemcitabine vs
cyclophosphamide, and the lack of negative pharmacokinetic
interference explain the good tolerability of the GET regimen
(Fogli et al, 2002). The more favourable patient characteristics
(younger median age, excellent performance status) and the
shorter treatment duration (four courses in the present trial, six
to eight courses in the GET trials in advanced breast cancer) can
explain the extremely low incidence of febrile neutropenia
observed in the present trial in comparison to the other trials
with the GET regimen (Conte et al, 2001; Zielinski et al, 2003;
Cappuzzo et al, 2004).
The primary aim of our study was to evaluate the activity of
the GET combination. The overall response rate was 87.8%, with
26.8% clinical complete remissions and 14.6% pCRs.
Conservative surgery was not an end point of the study and no
guideline for conservative surgery was included in the protocol;
this reason and the fact that the patients were treated in five
different hospitals may explain the relatively low percentage of
conservative surgery (44%). The high activity of this triplet
regimen has been confirmed by Hamm et al (2003) in locally
advanced breast cancer, and by Schneeweiss et al (2004) in
operable breast cancer. In this last trial, paclitaxel was substituted
with docetaxel (75mgm
 2), the dose of gemcitabine was reduced
to 800mgm
 2 on days 1 and 8, epirubicin was administered at
90mgm
 2 and filgrastim support was required.
Comparable pCR rates have been obtained with other regimens
containing taxanes, anthracyclines or antimetabolites (Gradishar,
1997; Ganem et al, 2003; Dieras et al, 2004; Lebowitz et al, 2004;
Smith et al, 2004). Differences in patient selection, tumour size and
characteristics, treatment duration and pathological classification
of response make any comparison impossible. It is, however, of
interest that the GET regimen allows the concurrent administra-
tion of full doses of active drugs, thus producing results
comparable to those obtained with more prolonged sequential
schedules (Gianni et al, 2002; Smith et al, 2002; Bear et al, 2003;
von Minckwitz et al, 2003).
Primary chemotherapy provides the ideal setting to investigate
prognostic and predictive factors; apart from pCR, the most
powerful predictor of long-term outcome is the status of axillary
lymph nodes. In our study, 36.6% of the patients had negative
axillary lymph nodes at surgery. However, the nodal status was
not pathologically documented at study entry, and it is therefore
impossible to measure the effect of treatment on this parameter.
Many predictive factors of response have been studied, and several
authors have reported that hormone receptor negativity, high
histological grade and high Ki-67 levels correlate with pCR, while
the predictive value of Her 2 expression, bcl-2 and p53 status
is still unclear (Archer et al, 1995; Makris et al, 1997; Chang et al,
1999; Colleoni et al, 1999; Ellis et al, 2001; Petit et al, 2001). In
our study the probability of pCR was higher, even if statistically
not significant, in the case of hormone receptor-negative tumours
Table 2 Haematological toxicity (% of patients)
Grade 1 Grade 2 Grade 3 Grade 4
Anaemia 53.5 27.9 2.3 —
Neutropenia 2.3 9.3 16.3 67.4
Leucopenia 7.0 30.2 44.2 14.0
Thrombocytopenia 34.9 16.3 9.3 —
Table 3 Non-haematological toxicity (% of patients)
Grade 1 Grade 2 Grade 3 Grade 4
Nausea/vomiting 39.5 37.2 9.3 —
Mucositis 27.9 9.3 7.0 —
Paresthesias 16.3 2.3 — —
Cutaneous 27.9 14.0 — —
Diarrhoea 11.6 0.0 2.3 —
Alopecia — 4.7 95.3 —
Table 4 Modification of tumour phenotype
Pretreatment
(% of patients)
Post-treatment
(% of patients) P
Oestrogen-receptor
positive
69.7 73.9 0.90
Grade 3 68.5 72.7 0.96
Mib 1 X20% 71.4 28.6 o0.05
Her-2 neu 21.0 10.5 0.46
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expression (20 vs 4%).
Availability of tumour tissue before, during and after PCT allows
for the possibility of measuring biomarker expression during
treatment and, potentially, correlating the observed modifications
with outcome. In particular, the tumour-proliferative rate mea-
sured as Ki-67, Mib-1 or thymidine labelling index is rapidly and
significantly inhibited by hormonal treatment or chemotherapy
(Collecchi et al, 1998; Colleoni et al, 1999; Archer et al, 2003). We
have previously reported in locally advanced breast cancer studies
that inhibition of tumour proliferation after PCT predicts a better
outcome (Collecchi et al, 1998). In this study, we have shown that
Mib-1 level was significantly lower after four courses of GET
(Mib-1 X20% in 71.4 and in 21.6% of the patients before and after
chemotherapy, respectively, Po0.05); however, the limited sample
size and the low number of events do not allow this finding to be
correlated with patient outcome.
Primary chemotherapy can facilitate the development of
treatments tailored on the quality of response (pCR vs non-pCR)
and biomarker expression and modulation. In this setting, the
expression of gene profile measured by DNA microarray offers the
opportunity to identify predictive markers of response; this allows
us to identify the patients who benefit from the treatment and to
spare unnecessary toxicities to those with de novo resistant
tumours (Buchholz et al, 2002; van de Vijver et al, 2002; van’t Veer
et al, 2002; Chang et al, 2003; Pusztai et al, 2003).
In conclusion, we have shown that four courses of preoperative
GET are safe and highly active in patients with early-stage
breast cancer. This tolerability is worth noting, taking into account
that all drugs were administered at nearly full doses, and this
regimen can represent an alternative to the sequential adminis-
tration of myelotoxic drugs. However, in order to exploit all
the opportunities offered by preoperative treatments, a coordi-
nated multidisciplinary approach including clinical oncologists,
pathologists and molecular biologists is required (Buchholz
et al, 2003).
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